{"gene":"RNF14","run_date":"2026-06-10T06:43:37","timeline":{"discoveries":[{"year":1999,"finding":"ARA54 (RNF14) was identified as a ligand-dependent androgen receptor (AR) coactivator that enhances AR-mediated transactivation; the C-terminal domain of ARA54 acts as a dominant-negative inhibitor of AR transcriptional activity, and ARA54 can co-operate additively with other AR coactivators (ARA70, SRC-1).","method":"Yeast two-hybrid screening, transient transfection/reporter assays in DU145 prostate cancer cells, dominant-negative truncation experiments","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — yeast two-hybrid plus mammalian cell reporter assays and dominant-negative dissection, single lab but multiple orthogonal methods","pmids":["10085091"],"is_preprint":false},{"year":2001,"finding":"ARA54 (RNF14) contains a RING finger domain that interacts specifically with class III ubiquitin-conjugating enzymes (UBE2E2, UbcH6, UBE2E3) via their UBC domain; wild-type ARA54 catalyzes E2-dependent autoubiquitination in vitro, whereas RING point mutant ARA54-C220S shows markedly reduced ubiquitination activity, establishing ARA54 as an E3 ubiquitin ligase.","method":"Yeast two-hybrid with deletion and point mutants, in vitro ubiquitination assay with insect-cell-expressed protein, in vivo ubiquitination in COS-7 cells with proteasome inhibitor (MG132)","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro reconstituted ubiquitination assay plus RING point mutagenesis plus in vivo proteasome-inhibitor rescue, multiple orthogonal methods in one study","pmids":["11322894"],"is_preprint":false},{"year":2001,"finding":"A point mutation at amino acid 472 (E→K) of ARA54 creates a dominant-negative inhibitor (mt-ARA54) that disrupts ARA54 homodimerization/oligomerization and suppresses AR transactivation and prostate cancer cell growth; ARA54 dimerization is required for enhancement of AR transactivation.","method":"In vitro mutagenesis, yeast two-hybrid, transient and stable transfection assays, doxycycline-inducible stable transfection in LNCaP cells, mammalian two-hybrid assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — mutagenesis combined with mammalian two-hybrid and stable cell-line functional assays, single lab","pmids":["11673464"],"is_preprint":false},{"year":2001,"finding":"ARA54 (RNF14) localizes to both cytoplasm and nucleus (whereas the related RING protein RNF8 localizes exclusively to the nucleus), as determined by GFP fusion imaging.","method":"GFP chimera transfection and fluorescence microscopy in COS-7 cells","journal":"European journal of biochemistry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single localization experiment with GFP fusion, single lab, no functional consequence linked","pmids":["11322894"],"is_preprint":false},{"year":2006,"finding":"Transgelin suppresses AR transactivation by interrupting ARA54 homodimerization and AR–ARA54 heterodimerization, causing cytoplasmic retention of both AR and ARA54; this suppression requires the presence of ARA54 (ARA54-siRNA abolishes the effect), demonstrating ARA54 dimerization is mechanistically required for AR nuclear coactivation.","method":"Co-immunoprecipitation, co-localization/subcellular fractionation, stable transfection, siRNA knockdown, reporter assays in LNCaP cells","journal":"Molecular endocrinology (Baltimore, Md.)","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — reciprocal functional rescue by siRNA plus co-IP and localization data, single lab","pmids":["17082327"],"is_preprint":false},{"year":2006,"finding":"hnRNP A1 suppresses ARA54-enhanced AR transactivation by disrupting the AR–ARA54 interaction and ARA54 homodimerization; this suppression is ARA54-dependent (abolished by ARA54-siRNA), placing hnRNP A1 as a negative regulator acting through ARA54.","method":"Co-immunoprecipitation, transient and stable transfection, siRNA knockdown, reporter assays in LNCaP cells","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — siRNA rescue experiment plus co-IP plus reporter assays, single lab","pmids":["17110431"],"is_preprint":false},{"year":2007,"finding":"ARA54 (RNF14) promotes cyclin D1 gene transcription in an AR-independent manner in human cancer cells; siRNA depletion of endogenous ARA54 reduces cyclin D1 mRNA and protein by suppressing transcription (not by altering stability), causing G1 arrest.","method":"siRNA knockdown, RT-PCR/qPCR, Western blot, mRNA/protein stability assays, cell-cycle FACS analysis in T98G cells","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — siRNA loss-of-function with defined transcriptional readout and cell-cycle phenotype, single lab, multiple orthogonal readouts","pmids":["17510080"],"is_preprint":false},{"year":2015,"finding":"ARA54 (RNF14) acts as the E3 ubiquitin ligase for neuropathy target esterase (NTE): ARA54 directly interacts with NTE, overexpression of ARA54 downregulates NTE protein levels via the ubiquitin-proteasome pathway, knockdown of ARA54 inhibits NTE degradation, and mutation of the ARA54 RING domain abolishes this activity.","method":"Co-immunoprecipitation (direct interaction), overexpression and siRNA knockdown with Western blot, RING domain point mutagenesis, proteasome inhibitor treatment","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RING mutagenesis plus co-IP plus siRNA rescue, single lab, multiple orthogonal methods","pmids":["26606397"],"is_preprint":false},{"year":2023,"finding":"RNF14 is the E3 ubiquitin ligase required for the translation-coupled resolution of covalent RNA-protein crosslinks: ribosome collisions at mRNA-crosslinked proteins trigger RNF14-dependent modification with atypical K6- and K48-linked ubiquitin chains on the crosslinked protein adducts, leading to their proteasomal degradation.","method":"PAR-CL crosslinking system in human cells, ubiquitin chain-linkage mass spectrometry, genetic depletion/knockout of RNF14, ribosome profiling, proteasome inhibitor assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (MS ubiquitin-chain typing, genetic KO, ribosome profiling, proteasome assays) in a single rigorous study establishing mechanism","pmids":["37951216"],"is_preprint":false}],"current_model":"RNF14 (ARA54) is a RING-domain E3 ubiquitin ligase that partners with class III E2 enzymes (UBE2E family) to catalyze substrate ubiquitination; it resolves aldehyde-induced RNA-protein crosslinks during translation by ubiquitylating ribosome-stalled crosslinked proteins with atypical K6/K48-linked chains for proteasomal degradation, ubiquitinates and destabilizes specific nuclear substrates such as NTE, and also functions as a ligand-dependent androgen receptor coactivator whose activity depends on its homodimerization and is negatively regulated by transgelin and hnRNP A1 through disruption of ARA54–AR complexes."},"narrative":{"mechanistic_narrative":"RNF14 (ARA54) is a RING-domain E3 ubiquitin ligase that couples substrate ubiquitination to transcriptional and translational quality-control processes [PMID:11322894, PMID:37951216]. Its catalytic activity depends on an intact RING domain, through which it engages class III ubiquitin-conjugating enzymes (UBE2E2, UbcH6/UBE2E1, UBE2E3) to drive E2-dependent ubiquitination, with the RING point mutant C220S abolishing this activity [PMID:11322894]. In its best-defined role, RNF14 resolves aldehyde-induced covalent RNA-protein crosslinks during translation: ribosome collisions at mRNA-crosslinked protein adducts trigger RNF14-dependent decoration of the adducts with atypical K6- and K48-linked ubiquitin chains, targeting them for proteasomal degradation [PMID:37951216]. RNF14 also acts as a substrate-selective ligase in the nucleus, directly binding neuropathy target esterase (NTE) and promoting its proteasomal degradation in a RING-dependent manner [PMID:26606397]. Independently of its ligase output, RNF14 functions as a ligand-dependent androgen receptor (AR) coactivator that enhances AR-mediated transactivation, an activity requiring RNF14 homodimerization; transgelin and hnRNP A1 negatively regulate this function by disrupting RNF14 homodimerization and AR–RNF14 complexes [PMID:10085091, PMID:11673464, PMID:17082327, PMID:17110431]. RNF14 additionally promotes cyclin D1 transcription in an AR-independent manner, and its depletion causes G1 arrest [PMID:17510080].","teleology":[{"year":1999,"claim":"Established RNF14's first functional context by showing it is a ligand-dependent AR coactivator, framing it as a modulator of nuclear receptor transcription rather than an orphan RING protein.","evidence":"Yeast two-hybrid screen plus reporter assays and dominant-negative truncation in DU145 prostate cancer cells","pmids":["10085091"],"confidence":"Medium","gaps":["Did not define a catalytic or enzymatic activity","Mechanism of AR enhancement at the molecular level unresolved"]},{"year":2001,"claim":"Defined RNF14 as a bona fide E3 ubiquitin ligase by mapping its RING-domain dependence and class III E2 partnership, converting it from a transcriptional cofactor into an enzyme.","evidence":"Yeast two-hybrid with deletion/point mutants, in vitro autoubiquitination with insect-cell protein, and in vivo ubiquitination with MG132 in COS-7 cells","pmids":["11322894"],"confidence":"High","gaps":["No physiological substrate identified at this stage","Functional link between ligase activity and AR coactivation not established"]},{"year":2001,"claim":"Showed that RNF14 homodimerization is mechanistically required for AR coactivation, identifying oligomerization as a regulatable node controlling its transcriptional function.","evidence":"Mutagenesis (E472K), mammalian two-hybrid, and doxycycline-inducible stable transfection assays in LNCaP cells","pmids":["11673464"],"confidence":"Medium","gaps":["Structural basis of dimerization not resolved","Relationship between dimerization and ligase activity unclear"]},{"year":2001,"claim":"Localized RNF14 to both cytoplasm and nucleus, consistent with dual roles in transcription and post-transcriptional control.","evidence":"GFP-fusion fluorescence microscopy in COS-7 cells","pmids":["11322894"],"confidence":"Low","gaps":["Single localization experiment with GFP fusion, no functional consequence linked","No characterization of regulated trafficking between compartments"]},{"year":2006,"claim":"Identified transgelin and hnRNP A1 as negative regulators that act by disrupting RNF14 homodimerization and AR–RNF14 complexes, explaining how RNF14 coactivation is restrained.","evidence":"Co-immunoprecipitation, subcellular localization, and siRNA rescue with reporter assays in LNCaP cells","pmids":["17082327","17110431"],"confidence":"Medium","gaps":["Whether regulation depends on RNF14 ligase activity not tested","In vivo relevance to prostate cancer progression not established"]},{"year":2007,"claim":"Revealed an AR-independent transcriptional role by showing RNF14 drives cyclin D1 transcription and is required to prevent G1 arrest, broadening its function beyond nuclear-receptor signaling.","evidence":"siRNA knockdown with qPCR, Western blot, mRNA/protein stability assays, and cell-cycle FACS in T98G cells","pmids":["17510080"],"confidence":"Medium","gaps":["Direct mechanism by which RNF14 promotes cyclin D1 transcription unknown","Whether ubiquitin ligase activity is involved unresolved"]},{"year":2015,"claim":"Provided the first defined physiological substrate by establishing RNF14 as the E3 ligase that ubiquitinates and destabilizes NTE, linking its catalytic activity to control of a specific nuclear target.","evidence":"Co-IP for direct interaction, overexpression/siRNA with Western blot, RING point mutagenesis, and proteasome inhibition","pmids":["26606397"],"confidence":"Medium","gaps":["Ubiquitin chain linkage on NTE not characterized","Physiological context of NTE regulation not defined"]},{"year":2023,"claim":"Defined RNF14's most mechanistically resolved role: translation-coupled resolution of RNA-protein crosslinks via ribosome-collision-triggered K6/K48 ubiquitination of crosslinked adducts for proteasomal degradation.","evidence":"PAR-CL crosslinking in human cells, ubiquitin chain-linkage mass spectrometry, RNF14 knockout, ribosome profiling, and proteasome inhibitor assays","pmids":["37951216"],"confidence":"High","gaps":["E2 partner used in this pathway not specified","How RNF14 is recruited to collided ribosomes not defined","Relationship to its nuclear/transcriptional roles unknown"]},{"year":null,"claim":"It remains unknown how RNF14's distinct activities — AR coactivation, cyclin D1 transcription, NTE degradation, and translation-coupled crosslink resolution — are integrated or whether they share a common regulatory logic.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model connecting transcriptional and quality-control functions","Mechanism distinguishing ligase-dependent from ligase-independent roles unresolved","Recruitment determinants for each substrate context undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[1,7,8]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,7,8]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,6]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,7,8]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[8]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,6]}],"complexes":[],"partners":["AR","UBE2E2","UBE2E3","NTE","TAGLN","HNRNPA1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9UBS8","full_name":"E3 ubiquitin-protein ligase RNF14","aliases":["Androgen receptor-associated protein 54","HFB30","RING finger protein 14"],"length_aa":474,"mass_kda":53.8,"function":"E3 ubiquitin-protein ligase that plays a key role in the RNF14-RNF25 translation quality control pathway, a pathway that takes place when a ribosome has stalled during translation, and which promotes ubiquitination and degradation of translation factors on stalled ribosomes (PubMed:36638793, PubMed:37651229, PubMed:37951215, PubMed:37951216). Recruited to stalled ribosomes by the ribosome collision sensor GCN1 and mediates 'Lys-6'-linked ubiquitination of target proteins, leading to their degradation (PubMed:36638793, PubMed:37651229, PubMed:37951215, PubMed:37951216). Mediates ubiquitination of EEF1A1/eEF1A and ETF1/eRF1 translation factors on stalled ribosomes, leading to their degradation (PubMed:36638793, PubMed:37651229). Also catalyzes ubiquitination of ribosomal proteins RPL0, RPL1, RPL12, RPS13 and RPS17 (PubMed:36638793). Specifically required to resolve RNA-protein cross-links caused by reactive aldehydes, which trigger translation stress by stalling ribosomes: acts by catalying 'Lys-6'-linked ubiquitination of RNA-protein cross-links, leading to their removal by the ATP-dependent unfoldase VCP and subsequent degradation by the proteasome (PubMed:37951215, PubMed:37951216). Independently of its function in the response to stalled ribosomes, acts as a regulator of transcription in Wnt signaling via its interaction with TCF transcription factors (TCF7/TCF1, TCF7L1/TCF3 and TCF7L2/TCF4) (PubMed:23449499). May also play a role as a coactivator for androgen- and, to a lesser extent, progesterone-dependent transcription (PubMed:19345326)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9UBS8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RNF14","classification":"Not Classified","n_dependent_lines":57,"n_total_lines":1208,"dependency_fraction":0.04718543046357616},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RNF14","total_profiled":1310},"omim":[{"mim_id":"605675","title":"RING FINGER PROTEIN 14; RNF14","url":"https://www.omim.org/entry/605675"},{"mim_id":"313700","title":"ANDROGEN RECEPTOR; AR","url":"https://www.omim.org/entry/313700"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/RNF14"},"hgnc":{"alias_symbol":["ARA54","HFB30","TRIAD2"],"prev_symbol":[]},"alphafold":{"accession":"Q9UBS8","domains":[{"cath_id":"3.10.110.10","chopping":"4-149_186-190","consensus_level":"high","plddt":87.0447,"start":4,"end":190},{"cath_id":"3.30.40.10","chopping":"217-303","consensus_level":"medium","plddt":91.016,"start":217,"end":303},{"cath_id":"-","chopping":"405-463","consensus_level":"medium","plddt":87.6395,"start":405,"end":463},{"cath_id":"1.10.287","chopping":"353-403","consensus_level":"medium","plddt":84.9455,"start":353,"end":403}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UBS8","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UBS8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UBS8-F1-predicted_aligned_error_v6.png","plddt_mean":82.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RNF14","jax_strain_url":"https://www.jax.org/strain/search?query=RNF14"},"sequence":{"accession":"Q9UBS8","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UBS8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UBS8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UBS8"}},"corpus_meta":[{"pmid":"10085091","id":"PMC_10085091","title":"Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10085091","citation_count":183,"is_preprint":false},{"pmid":"11322894","id":"PMC_11322894","title":"N-Terminally extended human ubiquitin-conjugating enzymes (E2s) mediate the ubiquitination of RING-finger proteins, ARA54 and RNF8.","date":"2001","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11322894","citation_count":85,"is_preprint":false},{"pmid":"17082327","id":"PMC_17082327","title":"Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth.","date":"2006","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/17082327","citation_count":75,"is_preprint":false},{"pmid":"11673464","id":"PMC_11673464","title":"A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11673464","citation_count":54,"is_preprint":false},{"pmid":"37951216","id":"PMC_37951216","title":"RNF14-dependent atypical ubiquitylation promotes translation-coupled resolution of RNA-protein crosslinks.","date":"2023","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/37951216","citation_count":42,"is_preprint":false},{"pmid":"17110431","id":"PMC_17110431","title":"Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonucleoprotein A1 via interaction with androgen receptor coregulator ARA54.","date":"2006","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17110431","citation_count":16,"is_preprint":false},{"pmid":"36482019","id":"PMC_36482019","title":"Long non-coding RNA SNHG4 enhances RNF14 mRNA stability to promote the progression of colorectal cancer by recruiting TAF15 protein.","date":"2022","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/36482019","citation_count":15,"is_preprint":false},{"pmid":"17510080","id":"PMC_17510080","title":"ARA54 is involved in transcriptional regulation of the cyclin D1 gene in human cancer cells.","date":"2007","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/17510080","citation_count":15,"is_preprint":false},{"pmid":"10320776","id":"PMC_10320776","title":"Isolation and characterization of a novel human gene (HFB30) which encodes a protein with a RING finger motif.","date":"1999","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10320776","citation_count":13,"is_preprint":false},{"pmid":"24472305","id":"PMC_24472305","title":"RNF14 is a regulator of mitochondrial and immune function in muscle.","date":"2014","source":"BMC systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/24472305","citation_count":8,"is_preprint":false},{"pmid":"26606397","id":"PMC_26606397","title":"Neuropathy Target Esterase Is Degraded by the Ubiquitin-Proteasome Pathway with ARA54 as the Ubiquitin Ligase.","date":"2015","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26606397","citation_count":3,"is_preprint":false},{"pmid":"33921921","id":"PMC_33921921","title":"Toxin Removal and Inflammatory State Modulation during Online Hemodiafiltration Using Two Different Dialyzers (TRIAD2 Study).","date":"2021","source":"Methods and protocols","url":"https://pubmed.ncbi.nlm.nih.gov/33921921","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":8124,"output_tokens":2369,"usd":0.029954,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9494,"output_tokens":2996,"usd":0.061185,"stage2_stop_reason":"end_turn"},"total_usd":0.091139,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"ARA54 (RNF14) was identified as a ligand-dependent androgen receptor (AR) coactivator that enhances AR-mediated transactivation; the C-terminal domain of ARA54 acts as a dominant-negative inhibitor of AR transcriptional activity, and ARA54 can co-operate additively with other AR coactivators (ARA70, SRC-1).\",\n      \"method\": \"Yeast two-hybrid screening, transient transfection/reporter assays in DU145 prostate cancer cells, dominant-negative truncation experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — yeast two-hybrid plus mammalian cell reporter assays and dominant-negative dissection, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"10085091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ARA54 (RNF14) contains a RING finger domain that interacts specifically with class III ubiquitin-conjugating enzymes (UBE2E2, UbcH6, UBE2E3) via their UBC domain; wild-type ARA54 catalyzes E2-dependent autoubiquitination in vitro, whereas RING point mutant ARA54-C220S shows markedly reduced ubiquitination activity, establishing ARA54 as an E3 ubiquitin ligase.\",\n      \"method\": \"Yeast two-hybrid with deletion and point mutants, in vitro ubiquitination assay with insect-cell-expressed protein, in vivo ubiquitination in COS-7 cells with proteasome inhibitor (MG132)\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro reconstituted ubiquitination assay plus RING point mutagenesis plus in vivo proteasome-inhibitor rescue, multiple orthogonal methods in one study\",\n      \"pmids\": [\"11322894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"A point mutation at amino acid 472 (E→K) of ARA54 creates a dominant-negative inhibitor (mt-ARA54) that disrupts ARA54 homodimerization/oligomerization and suppresses AR transactivation and prostate cancer cell growth; ARA54 dimerization is required for enhancement of AR transactivation.\",\n      \"method\": \"In vitro mutagenesis, yeast two-hybrid, transient and stable transfection assays, doxycycline-inducible stable transfection in LNCaP cells, mammalian two-hybrid assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — mutagenesis combined with mammalian two-hybrid and stable cell-line functional assays, single lab\",\n      \"pmids\": [\"11673464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ARA54 (RNF14) localizes to both cytoplasm and nucleus (whereas the related RING protein RNF8 localizes exclusively to the nucleus), as determined by GFP fusion imaging.\",\n      \"method\": \"GFP chimera transfection and fluorescence microscopy in COS-7 cells\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single localization experiment with GFP fusion, single lab, no functional consequence linked\",\n      \"pmids\": [\"11322894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Transgelin suppresses AR transactivation by interrupting ARA54 homodimerization and AR–ARA54 heterodimerization, causing cytoplasmic retention of both AR and ARA54; this suppression requires the presence of ARA54 (ARA54-siRNA abolishes the effect), demonstrating ARA54 dimerization is mechanistically required for AR nuclear coactivation.\",\n      \"method\": \"Co-immunoprecipitation, co-localization/subcellular fractionation, stable transfection, siRNA knockdown, reporter assays in LNCaP cells\",\n      \"journal\": \"Molecular endocrinology (Baltimore, Md.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — reciprocal functional rescue by siRNA plus co-IP and localization data, single lab\",\n      \"pmids\": [\"17082327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"hnRNP A1 suppresses ARA54-enhanced AR transactivation by disrupting the AR–ARA54 interaction and ARA54 homodimerization; this suppression is ARA54-dependent (abolished by ARA54-siRNA), placing hnRNP A1 as a negative regulator acting through ARA54.\",\n      \"method\": \"Co-immunoprecipitation, transient and stable transfection, siRNA knockdown, reporter assays in LNCaP cells\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — siRNA rescue experiment plus co-IP plus reporter assays, single lab\",\n      \"pmids\": [\"17110431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ARA54 (RNF14) promotes cyclin D1 gene transcription in an AR-independent manner in human cancer cells; siRNA depletion of endogenous ARA54 reduces cyclin D1 mRNA and protein by suppressing transcription (not by altering stability), causing G1 arrest.\",\n      \"method\": \"siRNA knockdown, RT-PCR/qPCR, Western blot, mRNA/protein stability assays, cell-cycle FACS analysis in T98G cells\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — siRNA loss-of-function with defined transcriptional readout and cell-cycle phenotype, single lab, multiple orthogonal readouts\",\n      \"pmids\": [\"17510080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ARA54 (RNF14) acts as the E3 ubiquitin ligase for neuropathy target esterase (NTE): ARA54 directly interacts with NTE, overexpression of ARA54 downregulates NTE protein levels via the ubiquitin-proteasome pathway, knockdown of ARA54 inhibits NTE degradation, and mutation of the ARA54 RING domain abolishes this activity.\",\n      \"method\": \"Co-immunoprecipitation (direct interaction), overexpression and siRNA knockdown with Western blot, RING domain point mutagenesis, proteasome inhibitor treatment\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RING mutagenesis plus co-IP plus siRNA rescue, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"26606397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"RNF14 is the E3 ubiquitin ligase required for the translation-coupled resolution of covalent RNA-protein crosslinks: ribosome collisions at mRNA-crosslinked proteins trigger RNF14-dependent modification with atypical K6- and K48-linked ubiquitin chains on the crosslinked protein adducts, leading to their proteasomal degradation.\",\n      \"method\": \"PAR-CL crosslinking system in human cells, ubiquitin chain-linkage mass spectrometry, genetic depletion/knockout of RNF14, ribosome profiling, proteasome inhibitor assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (MS ubiquitin-chain typing, genetic KO, ribosome profiling, proteasome assays) in a single rigorous study establishing mechanism\",\n      \"pmids\": [\"37951216\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RNF14 (ARA54) is a RING-domain E3 ubiquitin ligase that partners with class III E2 enzymes (UBE2E family) to catalyze substrate ubiquitination; it resolves aldehyde-induced RNA-protein crosslinks during translation by ubiquitylating ribosome-stalled crosslinked proteins with atypical K6/K48-linked chains for proteasomal degradation, ubiquitinates and destabilizes specific nuclear substrates such as NTE, and also functions as a ligand-dependent androgen receptor coactivator whose activity depends on its homodimerization and is negatively regulated by transgelin and hnRNP A1 through disruption of ARA54–AR complexes.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RNF14 (ARA54) is a RING-domain E3 ubiquitin ligase that couples substrate ubiquitination to transcriptional and translational quality-control processes [#1, #8]. Its catalytic activity depends on an intact RING domain, through which it engages class III ubiquitin-conjugating enzymes (UBE2E2, UbcH6/UBE2E1, UBE2E3) to drive E2-dependent ubiquitination, with the RING point mutant C220S abolishing this activity [#1]. In its best-defined role, RNF14 resolves aldehyde-induced covalent RNA-protein crosslinks during translation: ribosome collisions at mRNA-crosslinked protein adducts trigger RNF14-dependent decoration of the adducts with atypical K6- and K48-linked ubiquitin chains, targeting them for proteasomal degradation [#8]. RNF14 also acts as a substrate-selective ligase in the nucleus, directly binding neuropathy target esterase (NTE) and promoting its proteasomal degradation in a RING-dependent manner [#7]. Independently of its ligase output, RNF14 functions as a ligand-dependent androgen receptor (AR) coactivator that enhances AR-mediated transactivation, an activity requiring RNF14 homodimerization; transgelin and hnRNP A1 negatively regulate this function by disrupting RNF14 homodimerization and AR–RNF14 complexes [#0, #2, #4, #5]. RNF14 additionally promotes cyclin D1 transcription in an AR-independent manner, and its depletion causes G1 arrest [#6].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established RNF14's first functional context by showing it is a ligand-dependent AR coactivator, framing it as a modulator of nuclear receptor transcription rather than an orphan RING protein.\",\n      \"evidence\": \"Yeast two-hybrid screen plus reporter assays and dominant-negative truncation in DU145 prostate cancer cells\",\n      \"pmids\": [\"10085091\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not define a catalytic or enzymatic activity\", \"Mechanism of AR enhancement at the molecular level unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined RNF14 as a bona fide E3 ubiquitin ligase by mapping its RING-domain dependence and class III E2 partnership, converting it from a transcriptional cofactor into an enzyme.\",\n      \"evidence\": \"Yeast two-hybrid with deletion/point mutants, in vitro autoubiquitination with insect-cell protein, and in vivo ubiquitination with MG132 in COS-7 cells\",\n      \"pmids\": [\"11322894\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No physiological substrate identified at this stage\", \"Functional link between ligase activity and AR coactivation not established\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed that RNF14 homodimerization is mechanistically required for AR coactivation, identifying oligomerization as a regulatable node controlling its transcriptional function.\",\n      \"evidence\": \"Mutagenesis (E472K), mammalian two-hybrid, and doxycycline-inducible stable transfection assays in LNCaP cells\",\n      \"pmids\": [\"11673464\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of dimerization not resolved\", \"Relationship between dimerization and ligase activity unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Localized RNF14 to both cytoplasm and nucleus, consistent with dual roles in transcription and post-transcriptional control.\",\n      \"evidence\": \"GFP-fusion fluorescence microscopy in COS-7 cells\",\n      \"pmids\": [\"11322894\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single localization experiment with GFP fusion, no functional consequence linked\", \"No characterization of regulated trafficking between compartments\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified transgelin and hnRNP A1 as negative regulators that act by disrupting RNF14 homodimerization and AR–RNF14 complexes, explaining how RNF14 coactivation is restrained.\",\n      \"evidence\": \"Co-immunoprecipitation, subcellular localization, and siRNA rescue with reporter assays in LNCaP cells\",\n      \"pmids\": [\"17082327\", \"17110431\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether regulation depends on RNF14 ligase activity not tested\", \"In vivo relevance to prostate cancer progression not established\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Revealed an AR-independent transcriptional role by showing RNF14 drives cyclin D1 transcription and is required to prevent G1 arrest, broadening its function beyond nuclear-receptor signaling.\",\n      \"evidence\": \"siRNA knockdown with qPCR, Western blot, mRNA/protein stability assays, and cell-cycle FACS in T98G cells\",\n      \"pmids\": [\"17510080\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanism by which RNF14 promotes cyclin D1 transcription unknown\", \"Whether ubiquitin ligase activity is involved unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Provided the first defined physiological substrate by establishing RNF14 as the E3 ligase that ubiquitinates and destabilizes NTE, linking its catalytic activity to control of a specific nuclear target.\",\n      \"evidence\": \"Co-IP for direct interaction, overexpression/siRNA with Western blot, RING point mutagenesis, and proteasome inhibition\",\n      \"pmids\": [\"26606397\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitin chain linkage on NTE not characterized\", \"Physiological context of NTE regulation not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined RNF14's most mechanistically resolved role: translation-coupled resolution of RNA-protein crosslinks via ribosome-collision-triggered K6/K48 ubiquitination of crosslinked adducts for proteasomal degradation.\",\n      \"evidence\": \"PAR-CL crosslinking in human cells, ubiquitin chain-linkage mass spectrometry, RNF14 knockout, ribosome profiling, and proteasome inhibitor assays\",\n      \"pmids\": [\"37951216\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E2 partner used in this pathway not specified\", \"How RNF14 is recruited to collided ribosomes not defined\", \"Relationship to its nuclear/transcriptional roles unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown how RNF14's distinct activities — AR coactivation, cyclin D1 transcription, NTE degradation, and translation-coupled crosslink resolution — are integrated or whether they share a common regulatory logic.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model connecting transcriptional and quality-control functions\", \"Mechanism distinguishing ligase-dependent from ligase-independent roles unresolved\", \"Recruitment determinants for each substrate context undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [1, 7, 8]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 7, 8]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 7, 8]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 6]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"AR\", \"UBE2E2\", \"UBE2E3\", \"NTE\", \"TAGLN\", \"HNRNPA1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}